Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Prepaid Assets (2021 - 2025)

Amylyx Pharmaceuticals has reported Prepaid Assets over the past 5 years, most recently at $6.6 million for Q4 2025.

  • Quarterly results put Prepaid Assets at $6.6 million for Q4 2025, down 47.1% from a year ago — trailing twelve months through Dec 2025 was $6.6 million (down 47.1% YoY), and the annual figure for FY2025 was $6.6 million, down 47.1%.
  • Prepaid Assets for Q4 2025 was $6.6 million at Amylyx Pharmaceuticals, down from $9.3 million in the prior quarter.
  • Over the last five years, Prepaid Assets for AMLX hit a ceiling of $17.3 million in Q3 2023 and a floor of $5.4 million in Q4 2021.
  • Median Prepaid Assets over the past 5 years was $10.3 million (2022), compared with a mean of $10.9 million.
  • Biggest five-year swings in Prepaid Assets: surged 107.99% in 2023 and later tumbled 53.5% in 2025.
  • Amylyx Pharmaceuticals' Prepaid Assets stood at $5.4 million in 2021, then surged by 87.56% to $10.1 million in 2022, then skyrocketed by 47.64% to $14.9 million in 2023, then fell by 16.39% to $12.5 million in 2024, then crashed by 47.1% to $6.6 million in 2025.
  • The last three reported values for Prepaid Assets were $6.6 million (Q4 2025), $9.3 million (Q3 2025), and $6.0 million (Q2 2025) per Business Quant data.